Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.61 |
| ▸ | NCF1 | P14598 | 2/20 | 0.59 |
| ▸ | ACHE | P22303 | 2/20 | 0.53 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | HTR3A | P46098 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.45 |
| ▸ | HPGD | P15428 | 5/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.45 |
| ▸ | GLA | P06280 | 4/20 | 0.45 |
| ▸ | CASP1 | P29466 | 2/20 | 0.45 |
| ▸ | CASP7 | P55210 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | NQO2 | P16083 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6489480 | 0.79 | CYP1A2 (0.60) | TSHRNCF1ACHES1PR1OPRD1 | |
| SCHEMBL6213496 | 0.78 | S1PR1 (0.49) | TSHRNCF1S1PR1OPRD1ALDH1A1 | |
| SCHEMBL6457843 | 0.78 | S1PR1 (0.52) | TSHRNCF1S1PR1OPRD1ALDH1A1 | |
| SCHEMBL6489476 | 0.78 | S1PR1 (0.49) | TSHRNCF1S1PR1OPRD1ALDH1A1 | |
| SCHEMBL8366862 | 0.76 | KDM4E (0.53) | TSHRNCF1S1PR1OPRD1ALDH1A1 | |
| SCHEMBL7760642 | 0.75 | S1PR1 (0.47) | TSHRNCF1S1PR1OPRD1BACE1 | |
| SCHEMBL29557788 | 0.75 | NCF1 (1.00) | NCF1ACHEHTR3ABACE1ALDH1A1 | |
| SCHEMBL1120035 | 0.75 | NCF1 (1.00) | NCF1ACHEHTR3ABACE1ALDH1A1 | |
| SCHEMBL29690490 | 0.74 | NCF1 (0.64) | TSHRNCF1ACHEHTR3ABACE1 | |
| SCHEMBL323374 | 0.74 | NCF1 (0.64) | TSHRNCF1ACHEHTR3ABACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220296628-A1 | RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES | CUREVAC AG (DE) | 2022-09-22 | — | — | US | disclosed |
| EP-4013880-A1 | RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES | CureVac AG (DE) | 2022-06-22 | — | — | EP | disclosed |
| US-7410975-B2 | Small molecule toll-like receptor (TLR) antagonists | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-08-12 | — | — | US | disclosed |
| US-7410975-B2 | Small molecule toll-like receptor (TLR) antagonists | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-08-12 | — | — | US | disclosed |
| US-20070232622-A1 | Small molecule toll-like receptor (TLR) antagonists | COLEY PHARMACEUTICAL GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
| US-20070232622-A1 | Small molecule toll-like receptor (TLR) antagonists | COLEY PHARMACEUTICAL GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
| EP-1150977-B1 | PHENYL UREA AND PHENYL THIOUREA DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2004-08-25 | — | — | EP | disclosed |
| US-6699879-B1 | OBESITY, DIABETES, SLEEP DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-03-02 | — | — | US | disclosed |
| EP-1150977-A1 | PHENYL UREA AND PHENYL THIOUREA DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000047577-A1 | PHENYL UREA AND PHENYL THIOUREA DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2000-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232622-A1 | Small molecule toll-like receptor (TLR) antagonists | TLR3, TLR8, TLR7 | TSHR 2415/4885NCF1 1921/4885ACHE 4643/4885 |
| US-20220296628-A1 | RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES | TLR3, EIF2AK2, STING1 | TSHR 1136/4885NCF1 905/4885ACHE 4829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.